Zhejiang Orient Gene Biotech Co (SHSE:688298) Cyclically Adjusted Revenue per Share: ¥17.95 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688298 Zhejiang Orient Gene Biotech Co Ltd SHSE:688298
63 GF Score
Price ¥19.44
GF Value ¥30.43
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Zhejiang Orient Gene Biotech Co Cyclically Adjusted Revenue per Share?

Zhejiang Orient Gene Biotech Co SHSE:688298 -3.09% 63 Cyclically Adjusted Revenue per Share is ¥17.95 as of Mar. 2026. GuruFocus rates SHSE:688298 with a GF Score™ of 63/100 and a GF Value™ of ¥30.43 (Possible Value Trap). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zhejiang Orient Gene Biotech Co's adjusted revenue per share data for the fiscal year that ended in Dec. 2025 was ¥4.922. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥17.95 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-20), Zhejiang Orient Gene Biotech Co's current stock price is ¥ 19.44. Zhejiang Orient Gene Biotech Co's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2025 was ¥17.95. Zhejiang Orient Gene Biotech Co's Cyclically Adjusted PS Ratio of today is 1.08.

During the past 10 years, the highest Cyclically Adjusted PS Ratio of Zhejiang Orient Gene Biotech Co was 1.42. The lowest was 1.10. And the median was 1.36.


Zhejiang Orient Gene Biotech Co  (SHSE:688298) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zhejiang Orient Gene Biotech Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=19.44/17.95
=1.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 10 years, the highest Cyclically Adjusted PS Ratio of Zhejiang Orient Gene Biotech Co was 1.42. The lowest was 1.10. And the median was 1.36.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zhejiang Orient Gene Biotech Co Cyclically Adjusted Revenue per Share Related Terms


Zhejiang Orient Gene Biotech Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zhejiang Orient Gene Biotech Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Orient Gene Biotech Co Cyclically Adjusted Revenue per Share Chart

Zhejiang Orient Gene Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 17.95

Zhejiang Orient Gene Biotech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 17.95 0.00

SHSE:688298 vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Zhejiang Orient Gene Biotech Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Orient Gene Biotech Co Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zhejiang Orient Gene Biotech Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zhejiang Orient Gene Biotech Co's Cyclically Adjusted PS Ratio falls into.


SHSE:688298
63GF Score
Zhejiang Orient Gene Biotech Co Ltd SHSE:688298
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Orient Gene Biotech Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zhejiang Orient Gene Biotech Co's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=4.922/115.8323*115.8323
=4.922

Current CPI (Dec. 2025) = 115.8323.

Zhejiang Orient Gene Biotech Co Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 0.000 102.600 0.000
201712 1.481 104.500 1.642
201812 1.900 106.500 2.066
201912 2.424 111.200 2.525
202012 16.547 111.500 17.190
202112 70.616 113.108 72.317
202212 52.199 115.116 52.524
202312 4.064 114.781 4.101
202412 4.210 114.893 4.244
202512 4.922 115.832 4.922

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥17.95 mean?
Zhejiang Orient Gene Biotech Co (SHSE:688298) has a Cyclically Adjusted Revenue per Share of ¥17.95 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zhejiang Orient Gene Biotech Co and its competitors.
Is Zhejiang Orient Gene Biotech Co's Cyclically Adjusted Revenue per Share too high?
Zhejiang Orient Gene Biotech Co's current Cyclically Adjusted Revenue per Share is ¥17.95. Overall, Zhejiang Orient Gene Biotech Co has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Orient Gene Biotech Co's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Zhejiang Orient Gene Biotech Co's Cyclically Adjusted Revenue per Share of ¥17.95 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zhejiang Orient Gene Biotech Co and its competitors. Zhejiang Orient Gene Biotech Co's current Cyclically Adjusted Revenue per Share is ¥17.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Orient Gene Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Orient Gene Biotech Co (SHSE:688298) is currently considered Possible Value Trap. The stock's GF Value™ is ¥30.43, compared to a current price of ¥19.44 — trading 36.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥17.95. Zhejiang Orient Gene Biotech Co's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zhejiang Orient Gene Biotech Co (SHSE:688298), the current Cyclically Adjusted Revenue per Share is ¥17.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Orient Gene Biotech Co (SHSE:688298) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Orient Gene Biotech Co stock appears to be undervalued. The current stock price of ¥19.44 is trading 36.1% below its estimated GF Value™ of ¥30.43. GuruFocus considers Zhejiang Orient Gene Biotech Co to be Possible Value Trap.

Key valuation signals for SHSE:688298:

  • Cyclically Adjusted Revenue per Share: ¥17.95
  • GF Value™: ¥30.43 vs. price of ¥19.44 (36.1% below fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688298 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Orient Gene Biotech Co Business Description

Address 3787 East Section of Yangguang Avenue, Dipu Street, Anji County, Zhejiang Province, Huzhou, CHN, 313300
Zhejiang Orient Gene Biotech Co Ltd is engaged in production, research, development and sale of vitro diagnostic products. The company's products include Genetic diagnosis, Colloidal gold rapid diagnostic tests, Dry chemical strips (urinalysis), Bio-liquid diagnostic kits, Clinical test instruments, POCT time-resolved Fluor immunoassay Test kit (TRFI), and Raw materials.
63GF Score

Get the complete analysis for SHSE:688298

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥19.44
Price
¥30.43
GF Value